Please assess the completion status of the following clinical trial:

Trial Title: Dose-Ranging Study of Recombinant Human Papillomavirus Virus 16/18 Bivalent Vaccine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Written informed consent from the subject prior to enrolment;~* Female between, and including, 18 and 25 years of age at the time of enrolment;~* Subjects must be free of obvious health problems;~* Not pregnant and having no plan for pregnancy;~Exclusion Criteria:~* Pregnant or breastfeeding or having plan for pregnancy during the whole study (Month 0-7);~* Previous vaccination against HPV;~* Having severe allergic history or other immunodeficiency;~* Chemotherapy and other immunosuppressive agents using;

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 25 Years
- Healthy Volunteers: t

Study Arms:
- 30μg HPV (Type: EXPERIMENTAL): Participants in this arm would receive 30μg HPV vaccines which contains 20μg HPV 16 antigen and 10μg HPV 18 antigen
- 60μg HPV (Type: EXPERIMENTAL): Participants in this arm would receive 60μg HPV vaccines which contains 40μg HPV 16 antigen and 20μg HPV 18 antigen
- 90μg HPV (Type: EXPERIMENTAL): Participants in this arm would receive 90μg HPV vaccines which contains 60μg HPV 16 antigen and 30μg HPV 18 antigen
- hepatitis B vaccine (Type: PLACEBO_COMPARATOR): Participants in this arm would receive hepatitis B vaccine.

Based on this trial design, predict the completion outcome and termination type (if applicable).